Bookmark

Add to MyYahoo RSS

Myriad Genetics News

News on Myriad Genetics (Ticker: MYGN) continually updated from thousands of sources around the net.

11 hrs ago | Forward

How Angelina Jolie Changed Things For People With BRCA Mutations

"I can tell my children that they don't need to fear they will lose me to breast cancer," said actress Angelina Jolie last May when she announced that she underwent a preventive double mastectomy .

Comment?

Related Topix: Medicine, Health, Breast Cancer, Ovarian Cancer, US News, US Supreme Court, Biotech, Healthcare Industry, Genetics, Biology, Science

16 hrs ago | Bio IT World

GeneDx Seeks Invalidation of Myriad's BRCA Patents

GeneDx, a commercial genetic diagnostics lab located in Gaithersburg, Maryland, this week filed eleven petitions to invalidate patent claims held by Myriad Genetics, adding another new thread to the increasingly complicated web of litigation surrounding Myriad.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Genetics, Biology, Science, Patent / Trademark Law, Law

Mon Aug 18, 2014

Sys-Con Media

Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc.,...

These IPR petitions aim to nullify eleven patents owned, co-owned, or licensed by Myriad Genetics, Inc. These patents have been asserted against GeneDx in patent infringement litigation initiated in the United States District Court for the District of The patents at issue all deal with three genes involved in the diagnosis of cancer - two of the ... (more)

Comment?

Related Topix: Patent / Trademark Law, Law, Biotech, Medicine, BioReference Laboratories, Healthcare Industry

Fri Aug 15, 2014

AmericanBankingNews.com

Credit Suisse Reiterates "Neutral" Rating for Myriad Genetics

's stock had its "neutral" rating reaffirmed by equities researchers at Credit Suisse in a research report issued on Friday.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Genetics, Rules-Based Medicine, Myriad Pharmaceuticals

Wed Aug 13, 2014

Hispanic Business

Myriad Genetics Inc - 10-K - Management's Discussion and Analysis of...

We are a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of novel, transformative tests across major diseases.

Comment?

Related Topix: Biotech, Healthcare Industry, Genetics, Sales, Women's Health, Health

Salt Lake Tribune

Myriad's profits slip but revenues gain ground

The molecular-diagnostic company, which discovers and commercializes tests assessing a person's risk of developing a disease, had a net quarterly income of $37.1 million in the quarter ending June 30, down from $44.1 million a year earlier.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

SchaeffersResearch.com

Stocks On the Move: Kate Spade & Co, Myriad Genetics, Inc., and SeaWorld Entertainment Inc

The rally comes in the wake of encouraging comments from Sterne Agee, which believes the retailer's fundamentals make for a potential buying opportunity.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Financial Markets, Day Trading, Personal Finance

Barron's

Morning Movers: SeaWorld Slumps on Big Miss; Ford Gains on Upgrade

The less said about Tuesday the better because there wasn't much to say . Wednesday should provide more topics of conversation.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Watches, Fossil, Jewelry

Tue Aug 12, 2014

Investor's Business Daily

Myriad Genetics Guidance Disappoints, Q4 Edges Views

Gene-tester Myriad Genetics modestly beat fiscal Q4 estimates late Tuesday, but EPS guidance below consensus sent the stock falling 5% in after-hours trading.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Genetics, Rules-Based Medicine, Biology, Science, Myriad Pharmaceuticals

AmericanBankingNews.com

Myriad Genetics (MYGN) Releases Quarterly Earnings Results

Myriad Genetics posted its quarterly earnings results on Tuesday. The company reported $0.48 earnings per share for the quarter, beating the analysts' consensus estimate of $0.46 by $0.02, Analyst RN reports.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Genetics, Rules-Based Medicine, Myriad Pharmaceuticals

JD Supra

Examination of Myriad-Mayo Guidance Comments -- International Bioindustry Associations

On March 4, the U.S. Patent and Trademark Office issued a guidance memorandum, entitled "Guidance For Determining Subject Matter Eligibility Of Claims Reciting Or Involving Laws of Nature, Natural Phenomena, & Natural Products" , to implement a new procedure for determining the subject matter eligibility of claims under 35 U.S.C. 101 in view of the ... (more)

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Genetics, Science / Technology, Inventions, Agriculture, Science

Forward

Genetics Lab Refuses To Share Data That Could Save Lives

Myriad Genetics may have lost its singular hold on the market for BRCA1 and BRCA2 testing in May 2013 when the Supreme Court ruled against the patenting of genes , but few outside the science and medical communities are aware that Myriad continues to possess a repository of patient data from BRCA testing that it does not share with researchers ... (more)

Comment?

Related Topix: Biotech, Healthcare Industry, Genetics, Biology, Science

Mon Aug 11, 2014

IOMA

Bloomberg BNA Study Analyzes the Impact of Recent Supreme Court...

Home A Press A Legal & Business A Bloomberg BNA Study Analyzes the Impact of Recent Supreme Court Decisions That Leave Life Sciences Industry under Cloud of Uncertainty Bloomberg BNA Study Analyzes the Impact of Recent Supreme Court Decisions That Leave Life Sciences Industry under Cloud of Uncertainty - Bloomberg BNA and law firm Robins, Kaplan, ... (more)

Comment?

Related Topix: Biotech, Science / Technology, Law, Robins Kaplan Miller and Ciresi, Medicine, Healthcare Industry, Patent / Trademark Law, Inventions

AmericanBankingNews.com

Myriad Genetics (MYGN) Scheduled to Post Quarterly Earnings on Tuesday

Myriad Genetics is scheduled to issue its Q414 quarterly earnings data on Tuesday, August 12th.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Genetics, Rules-Based Medicine, Myriad Pharmaceuticals

Wed Aug 06, 2014

jdsupra.com

Examination of Myriad-Mayo Guidance Comments -- ACLU

On March 4, the U.S. Patent and Trademark Office issued a guidance memorandum entitled "Guidance For Determining Subject Matter Eligibility Of Claims Reciting Or Involving Laws of Nature, Natural Phenomena, & Natural Products" to implement a new procedure for determining the subject matter eligibility of claims under 35 U.S.C. 101 in view of the ... (more)

Comment?

Related Topix: ACLU, Biotech, Medicine, Healthcare Industry, Patent / Trademark Law, Law, Genetics

Thu Jul 31, 2014

jdsupra.com

The USPTO Issues Guidelines for Subject Matter Eligibility Analysis:...

On March 4th, 2014, the United States Patent and Trademark Office issued a guidance advising examiners and the public of the factors for determining whether an invention satisfies the provisions of 35 U.S.C. A 101, as applied to patent eligibility in view of the U.S. Supreme Court's decisions in Molecular Pathology v.

Comment?

Related Topix: Patent / Trademark Law, Law, USPTO, Inventions, Science / Technology, Biotech, Medicine, Healthcare Industry

The Washington Post

Gene Tests to Match Patients to Therapy to Get FDA Oversight

Commonly used tests to predict disease or match a cancer patient with the drug most likely to work will be more strictly regulated under a U.S. Food and Drug Administration proposal issued today.

Comment?

Related Topix: Healthcare Law, Law, Food and Drug Administration, Genetics, Medicine, Biotech, Healthcare Industry, Biology, Science, Myriad Pharmaceuticals

Forbes.com

FDA To Regulate Thousands Of Cancer, Genetic, And Other Diagnostics

The Food and Drug Administration unveiled plans to regulate thousands of diagnostic tests, including many coming from the exploding field of genetic research, to which it has until now turned a blind eye.

Comment?

Related Topix: Healthcare Law, Law, Food and Drug Administration, Genetics, Medicine, Biotech, Healthcare Industry, Business News

Wed Jul 30, 2014

GlobeNewswire

Myriad Genetics to Announce Financial Results for the Fiscal Fourth...

Myriad Genetics, Inc. today announced that it will issue financial results for the fiscal fourth quarter and full year 2014 as well as provide financial guidance for fiscal year 2015 following the close of market on Tuesday, August 12, 2014.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Genetics, Biology, Science, Rules-Based Medicine, Myriad Pharmaceuticals

Wed Jul 23, 2014

North County Public Radio

Biotech firm pulls out of Saranac Lake

The Village of Saranac Lake's plan to grow a cluster of biotechnology companies suffered a setback Monday.

Comment?

Related Topix: Saranac Lake, NY, Biotech, Science / Technology, Medicine, Healthcare Industry, Lake Placid, NY, Myriad Pharmaceuticals, Lake-Clear, NY

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••